INVO Bioscience Inc (INVO): Thank you!

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

INVO Bioscience Inc (INVO)

Reply Private New

Keep Last Read

Next 10 Prev Next

Send PM Follow Ignore

Followers	2426
Posts	90818
Boards Moderated	7
Alias Born	09/12/2003

Re: Mr. Zen post# 1106

Wednesday, 04/17/2024 1:48:25 PM

Wednesday, April 17, 2024 1:48:25 PM

Thank you!

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent INVO News

Micro Cap Massively Bid Up Before Opening Bell • AllPennyStocks.com • 04/17/2024 02:25:00 PM
INVO Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/16/2024 08:59:29 PM
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:24:52 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 02:01:07 PM
NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON) • GlobeNewswire Inc. • 01/23/2024 01:00:00 PM
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors • GlobeNewswire Inc. • 01/17/2024 01:00:00 PM
Form S-4 - Registration of securities, business combinations • Edgar (US Regulatory) • 01/16/2024 10:29:59 PM
Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/10/2024 09:46:12 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:05:33 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:29:45 PM
Form 424B7 - Prospectus [Rule 424(b)(7)] • Edgar (US Regulatory) • 12/28/2023 10:04:25 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 10:02:41 PM
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/13/2023 10:08:27 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 09:53:21 PM
NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal • PR Newswire (US) • 12/11/2023 01:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 10:18:38 PM
INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement • PR Newswire (US) • 11/28/2023 02:00:00 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/24/2023 06:08:33 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:59:42 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:10:41 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:06:04 PM
INVO Reports Record Third Quarter 2023 Financial Results • PR Newswire (US) • 11/13/2023 09:01:00 PM
Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 11/13/2023 02:23:51 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 02:21:54 PM
Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/13/2023 02:12:34 PM

More INVO News

InvestorsHub NewsWire

FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM

Start posting your company's news

Only $200 per official company press release!

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow